Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for chronic pruritus of unknown origin in adults
2021-004315-76Phase 3Active
- Sponsor
- Sanofi
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic pruritus comparing Dupilumab arm with Placebo arm (2 arms). Started Nov 2021; status: active.
02
Drugs
03
Conditions
chronic idiopathic pruritus
Beyond the preview
Go deeper on 2021-004315-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004315-76.